S-1: SRx Health Solutions Faces Going Concern Amid Losses, CCAA

SRx Health Solutions, Inc. is grappling with significant financial losses and a going concern warning, as its Canadian subsidiary enters creditor protection and the company registers 82 million shares for resale by Keystone Capital Partners.

Summary

• SRx Health Solutions, Inc. (formerly Better Choice Company Inc.) operates two segments: Canadian specialty pharmacy (SRx Health) and pet health and wellness (Halo).
• SRx Health Canada initiated CCAA (Companies Creditors Arrangement Act) proceedings on August 12, 2025, due to liquidity constraints and inability to refinance maturing obligations, securing $1.75 million in DIP financing.
• Net sales decreased by $76.0 million (65%) to $41.1 million for the nine months ended June 30, 2025, compared to $117.1 million for the same period in 2024, primarily due to operational disruptions and liquidity challenges.
• Gross profit decreased by $13.1 million (56%) to $10.3 million for the nine months ended June 30, 2025, from $23.4 million in 2024.
• Net loss increased significantly to $29.7 million for the nine months ended June 30, 2025, from $11.1 million in 2024.
• The company reported an accumulated deficit of $98.4 million and a working capital deficiency of $49.6 million as of June 30, 2025.
• SRx Canada is not in compliance with CWB loan covenants, resulting in $23.1 million of debt being classified as a current liability.
• Halo, the pet health and wellness subsidiary, exited Petco stores and its DTC channel in December 2023 and June 2024, respectively, to improve profitability, and sold its Asian business for $8.1 million.
• An Equity Line of Credit (ELOC) Purchase Agreement with Keystone Capital Partners, LLC was amended to $1.0 billion, with a $20.0 million convertible promissory note issued to Keystone.
• The company completed a July PIPE Financing of $7.65 million in senior secured convertible notes and warrants, and an October PIPE Financing raising approximately $15.23 million through preferred stock and warrants.
• Up to 82,000,000 shares of common stock are being registered for resale by Keystone Capital Partners, LLC, representing approximately 40.64% of total fully diluted outstanding shares.
• The company received a notice from NYSE American on October 14, 2025, regarding non-compliance with continued listing standards.

Sentiment

Score: 2

Explanation: The company faces severe financial challenges, including substantial losses, a significant accumulated deficit, and a going concern warning from auditors. Its Canadian subsidiary is in creditor protection, and the company is non-compliant with loan covenants and NYSE American listing standards. While new financing has been secured and strategic shifts are underway, the overall financial health is precarious, and significant dilution is expected.

Positives

• Secured Debtor-in-Possession (DIP) financing of up to $1.75 million for SRx Canada's working capital needs during CCAA proceedings.
• Halo, the pet health and wellness subsidiary, made strategic exits from Petco stores and its DTC channel to improve profitability.
• Halo sold its Asian business for $8.1 million, including $6.5 million in cash and a 5-year royalty agreement.
• Entered into an Equity Line of Credit (ELOC) Purchase Agreement with Keystone Capital Partners, LLC, providing access to up to $1.0 billion in capital, subject to conditions.
• Successfully completed July PIPE Financing, raising $7.65 million through senior secured convertible notes and warrants.
• Successfully completed October PIPE Financing, raising approximately $15.23 million through Series A convertible preferred stock and warrants.
• The company's specialty pharmacy network (SRx Network) is integrated across all 10 Canadian provinces, offering comprehensive, integrated, and customized specialty healthcare services.
• SRx Health's wholesale and distribution facility is Health Canada accredited, providing a competitive advantage in specialty drug access and distribution.
• The Canadian specialty pharmacy sub-sector shows robust growth, with specialty drug spend increasing by 9.7% from 2018-2022 and projected to account for over 50% of eligible insurance plan submissions by 2026.
• Aging demographics and increasing prevalence of chronic illnesses in Canada are driving demand for specialty pharmaceuticals.
• Expanding scope of pharmacist practice in Canada allows pharmacists to independently prescribe, renew, and adjust medications, and administer vaccinations, increasing accessibility to care.
• Robust specialty drug pipeline with 60% of new medications in development being specialty drugs, indicating future growth for specialty pharmacies.
• SRx Health's collaborative network and storefront presence provide quicker and more convenient access to pharmacists and integrated patient care compared to competitors.

Negatives

• SRx Canada is undergoing CCAA (Companies Creditors Arrangement Act) proceedings due to liquidity constraints and inability to refinance maturing obligations.
• Net sales decreased by $76.0 million (65%) to $41.1 million for the nine months ended June 30, 2025, primarily due to operational disruptions and liquidity constraints.
• Gross profit decreased by $13.1 million (56%) to $10.3 million for the nine months ended June 30, 2025.
• Net loss significantly increased to $29.7 million for the nine months ended June 30, 2025, from $11.1 million in 2024.
• The company has an accumulated deficit of $98.4 million and a working capital deficiency of $49.6 million as of June 30, 2025.
• SRx Canada is not in compliance with CWB loan covenants, leading to the classification of $23.1 million of debt as a current liability and making it callable by the lender.
• Independent auditors included an explanatory paragraph indicating substantial doubt about the company's ability to continue as a going concern.
• The sale of 82,000,000 shares by the Selling Stockholder (Keystone) could result in significant dilution (approximately 40.64% of fully diluted shares) and a decline in the public trading price.
• The company has historically incurred significant losses and expects to continue generating operating losses and consuming cash resources in the near term.
• Goodwill impairment charge of $26.91 million (CAD) for the year ended September 30, 2024, primarily due to the loss of a key contract and challenging industry dynamics in the Pharmacy and Prescription Drug Sales reporting unit.
• Intangible assets impairment loss of $2.1 million (CAD) for the year ended September 30, 2024, related to customer lists.
• The company's common stock price was $0.3000 per share on October 31, 2025, indicating a low market valuation.
• The company is a smaller reporting company, which may make its securities less attractive to investors and comparisons difficult.
• The company received a notice from NYSE American on October 14, 2025, regarding non-compliance with continued listing standards (stockholders' equity below $4 million and losses in three of four recent fiscal years).
• The company has until November 13, 2025, to submit a plan to regain compliance with NYSE American listing standards by July 14, 2026.
• The ELOC Purchase Agreement allows Keystone to purchase shares at a discount to the then-current closing sale price, potentially causing further price decline.
• Management will have broad discretion over the use of proceeds from ELOC sales, which may not necessarily improve financial condition or market value.
• The company does not expect to pay cash dividends in the foreseeable future.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to recurring losses, negative operating cash flows, and need for additional capital.
• Impact of damage to or interruption of information technology systems due to cyber-attacks or other circumstances beyond control.
• Business interruptions resulting from geopolitical actions, including war and terrorism.
• Inability to successfully implement growth strategy or manage anticipated growth effectively.
• Failure to achieve or maintain profitability.
• Loss of key members of senior management team.
• Inability to generate sufficient cash flow or raise capital on acceptable terms to run operations, service debt, and make necessary capital expenditures.
• Dependence on subsidiaries for payments, advances, and transfers of funds due to holding company status.
• Inability to successfully develop additional products and services or successfully market and commercialize them.
• Intense competition in the market from companies with greater resources.
• Inability to attract new and retain existing customers, suppliers, distributors, or retail partners.
• Allegations that products cause injury or illness or fail to comply with government regulations.
• Inability to manage supply chain effectively, including price increases and shortages of inputs.
• Inability of co-manufacturers and suppliers to comply with legal and regulatory requirements.
• Effect of potential price increases and shortages on inputs, commodities, and ingredients due to broader geopolitical and macroeconomic conditions.
• Inability to develop and maintain brand and brand reputation.
• Non-compliance with data privacy rules.
• Non-compliance with applicable regulations issued by the U.S. Food and Drug Administration (FDA), the U.S. Federal Trade Commission (FTC), the U.S. Department of Agriculture (USDA), and other federal, state, and local regulatory authorities.
• Risk of product recalls for various reasons, including defects, packaging safety, and inadequate labeling.
• Risk of shifting customer demand in relation to raw pet foods, premium kibble, and canned pet food products, and failure to respond quickly and effectively.
• Exposure to securities litigation or shareholder activism, incurring significant expense and hindering business execution.
• Highly regulated specialty pharmacy industry in Canada, with stringent federal and provincial governmental regulations and licensing requirements.
• Changes in reimbursement programs, prescription drug pricing, and commercial terms could adversely affect SRx Health's operations and financial performance.
• Inflationary pressures may affect drug costs and other operating costs.
• High competition in the specialty healthcare industry from larger competitors with more resources.
• Impact of interplay between brand name and generic drugs on profitability.
• Changes in drug development and prescription mix may impact SRx Health's results of operation.
• Product liability, product recall, or personal injury issues could damage SRx Health's reputation.
• Risk of defective or expired products, counterfeit products, errors in re-labeling, product tampering, contamination, or mishandling.
• Inventory reaching expiration dates and requiring write-downs.
• Disruption of distribution facilities critical to SRx Health's operations.
• High degree of risk in conducting clinical trials, including delays or stoppages beyond control.
• Negative results from clinical trials or adverse safety events involving product targets.
• Insurance policies may not be sufficient to cover all claims.
• Business continuity hazards and risks, including natural disasters, utility failures, cyber-attacks, and supply chain disruptions.
• Ineffectiveness of risk management policies and procedures.
• Reputational damages to SRx Health's suppliers impacting consumer opinion.
• Healthcare professional errors harming business and reputation.
• Consolidation in the supply chain negatively impacting drug prices and SRx Health's ability to compete.
• Reliance on third-party suppliers for a significant portion of products, leading to supply disruptions.
• Fluctuations in quarterly results of operations.
• Changes in tax and trade policies, tariffs, and other government regulations affecting trade between Canada and other countries.
• Disruption of the global supply chain and ineffective service providers.
• Failure to meet customer expectations due to changing preferences.
• Inability to keep pace with rapid developments in healthcare technology.
• Use and disclosure of personally identifiable information subject to privacy and security regulations.
• Reliance on relationships with major drug manufacturers and specialty practitioners.
• Information technology systems impairment and cyber-attacks.
• Services must integrate and interoperate with a variety of operating systems, software, hardware, web browsers, and networks.
• Failure to properly manage inventories and anticipate demand.
• Reliance on data obtained from third-party sources which may be inaccurate.
• Change in population demographics could have an adverse effect on SRx Health's business, operations, financial condition and results of operations.
• Inability to hire, retain, and motivate qualified personnel.
• Dependence on continued services and performance of senior management and other key employees.
• Involvement in regulatory or agency proceedings, investigations, and audits.
• Impact of economic conditions, including decreased spending on pets in a challenging economic climate.
• Inability to successfully implement SRx Health's growth strategy, including future acquisitions.
• Strain on management team and capital resources due to growth.
• Competition for acquisition candidates, consolidation within the pharmacy industry, and economic conditions limiting growth through acquisitions.
• Changes in the Canadian healthcare industry and regulatory environment negatively affecting growth and financial projections.
• Increases in sourcing, manufacturing, freight, and/or warehousing costs, supply shortages, interruption in Halo's sourcing operations.
• Failure to maintain and expand Halo's brand or product quality.
• Inability to compete effectively in the highly competitive pet health and wellness industry.
• Failure to attract new customers or retain existing customers in a cost-effective manner.
• Food safety and food-borne illness incidents affecting Halo's business.
• Inability to manage Halo's manufacturing and supply chain effectively.
• Delays or disruptions from independent shipping providers.
• Inadequate intellectual property rights protection for Halo's business.
• Claims of intellectual property infringement by third parties.
• Failure to comply with the U.S. Foreign Corrupt Practices Act, other anti-corruption laws, and trade control laws.
• Limitations on ability to utilize net operating loss carryforwards.
• Extensive governmental regulation of animal food products.
• International expansion of Halo's business exposing it to substantial risks.
• Changes in government regulations and trade policies, particularly with China.
• Product recalls for Halo's products.
• Holding company structure making the company dependent on subsidiaries for cash flow.
• Level of indebtedness and related covenants limiting operational and financial flexibility.
• Common stock may be deemed a penny stock, adversely affecting market price.
• Failure to meet NYSE American continued listing requirements.
• Volatile common stock prices.
• Issuance of preferred stock adversely affecting voting power or value of common stock.
• Administrative and regulatory costs of public company compliance.
• Being a smaller reporting company making securities less attractive.
• Dilution from sale or issuance of ordinary shares to Keystone.
• Keystone paying less than market price for shares, causing price decline.
• Management's broad discretion over use of proceeds from ELOC sales.

Future Outlook

The company anticipates increasing demand for specialty medications and health system capacity challenges to drive strong tailwinds for its model, positioning it to expand its leadership role in Canada's specialty healthcare landscape. Halo's future growth is expected to be driven by brand awareness, new consumer messaging, and innovation, with a shift in media investment to Amazon and Chewy platforms. However, the company expects ongoing margin variability due to macroeconomic factors, including inflationary pressures. It does not expect to achieve positive cash flow until the end of 2025 or longer and is actively evaluating strategic alternatives for the pet food business, including potential restructuring or divestiture. The company intends to increase its authorized capital and register additional shares under the ELOC Purchase Agreement, while continuing to implement cost control measures and operational efficiencies.

Management Comments

• Management believes it is in the company's best interests to have the flexibility to sell Common Shares pursuant to the ELOC Purchase Agreement, subject to market conditions.
• Halo management believes Halo is better equipped to customize products for the pet health and wellness market generally as compared to other companies in the industry.
• Halo management believes its overall relationships with its employees are positive and the strength of its team is a critical success factor in becoming the most innovative premium pet food company in the world.
• Halo management monitors changes in these laws and believes that Halo is in material compliance with applicable laws.

Industry Context

The Canadian specialty healthcare industry is characterized by high-cost, complex specialty drugs for chronic, rare diseases, requiring specialized infrastructure, which creates significant barriers to entry for traditional pharmacies. This sector is experiencing robust growth, with specialty drug spending increasing by 9.7% from 2018-2022 and projected to exceed 50% of eligible insurance plan submissions by 2026. Demographic shifts, including an aging Canadian population and rising chronic illnesses, are driving demand. The expanding scope of pharmacist practice in Canada, partly due to physician shortages, positions pharmacies as critical, accessible healthcare delivery channels. The pet health and wellness industry is highly competitive, driven by pet humanization and consumer focus on health, with a growing shift towards e-commerce for product sales.

Comparison to Industry Standards

• SRx Health's network of 20 specialty pharmacies, 34 infusion clinics, four clinical trials sites, patient support programs, and a Health Canada accredited wholesale facility across all 10 Canadian provinces positions it as one of the most accessible providers of comprehensive, integrated, and customized specialty healthcare services in Canada.
• The complex infrastructure and clinical oversight required for specialty drugs (typically exceeding US$6,000 annually) represent a significant barrier to entry for traditional retail pharmacies, giving SRx Health a competitive advantage.
• SRx Health is noted as one of only a few specialty pharmacy chains in Canada and the newest entrant in the space.
• SRx Health's brick-and-mortar retail presence in eight provinces provides an advantageous pharmacist-to-patient ratio and face-to-face interaction, differentiating it from competitors who often dispense from closed distribution facilities.
• SRx Health's average reimbursement submission time of 1.3 business days and average of 1.1 business days for first clinic appointments on a rush basis are significantly faster than the estimated industry standard of approximately three business days.
• Halo's premium and super-premium pet products (retail price > $0.20 per ounce) compete with major conventional brands like Mars, Nestlé, and J.M. Smucker Company, as well as specialty and natural brands such as Blue Buffalo, Wellness, Fromm, Orijen, Merrick, Stella and Chewy, Open Farm, and Freshpet.

Management Changes

Corporate Governance

Legal Proceedings

• On December 17, 2022, SRx Health was subject to discipline from the Saskatchewan College of Pharmacy Professionals due to improper billing practices, resulting in a CAD$30,000 fine, repayment of CAD$73,795.40 overbilled, and reimbursement of CAD$25,875.00 investigation costs; the matter has been resolved and was deemed immaterial.
• On August 12, 2025, SRx Canada obtained an Initial Order under the federal Companies Creditors Arrangement Act (CCAA) from the Ontario Superior Court of Justice (Commercial List) due to liquidity constraints and inability to refinance maturing obligations, including a stay of proceedings, appointment of a monitor, DIP financing, and a sale process.
• Neither the Company nor its U.S. subsidiary, Halo, has filed under any bankruptcy code or statutory reorganization scheme.
• The company is subject to tax examinations primarily for the years 2020 through 2024 in Canada.
• The company may be involved in legal proceedings, claims, and regulatory, tax, or government inquiries and investigations that arise in the ordinary course of business.

Related Party Transactions

• During fiscal years ended September 30, 2023 and 2024, SRx Canada engaged in non-interest-bearing working capital advances with its largest shareholder and entities under common control; these balances were reclassified to retained earnings as capital contributions and no amounts remain outstanding as of September 30, 2024.
• During the pre-merger period in the three months ended June 30, 2025, net related party balances transitioned into a payable position, including a $1.4 million balance due to Adesh Vora, the company's former Chief Executive Officer; this was recorded as an increase to beginning accumulated deficit and a non-cash capital distribution.
• On June 26, 2023, the company purchased all assets of Niagara Community Pharmacy Ltd. from its Chief Executive Officer, Adesh Vora's Professional Corporation, with terms and purchase price consistent with those negotiated between the vendor and the PC.
• On August 14, 2025, the company entered into a Settlement, Share Forfeiture and Mutual Release Agreement with certain founders and officers of SRx Canada (Forfeiting Stockholders), including Adesh Vora, who forfeited approximately 18,839,332 Exchangeable Shares.
• On August 25, 2025, the company issued 2,396,697 shares of restricted common stock as performance bonus compensation to certain directors, officers, and employees.
• On September 16, 2025, the company issued 196,000 shares of restricted common stock to certain current and former directors.
• Between July and September 2025, the company issued 394,780 shares of common stock pursuant to a retraction of shareholders' exchangeable shares, which converted into common stock; these shareholders were former employees and shareholders of SRx Canada that initially received exchangeable shares in the Merger.

Stakeholder Impact

• Shareholders face significant dilution risk (approximately 40.64% from Keystone resale), potential decline in stock price, no anticipated cash dividends, uncertainty regarding the company's ability to continue as a going concern, and potential loss of investment.
• Employees may be impacted by workforce reductions due to CCAA proceedings, but the company offers equity incentive plans and benefits to attract and retain talent.
• Customers experienced operational disruptions and liquidity constraints that limited the company's ability to purchase and dispense high-cost specialty medications, leading to reduced patient volumes and prescription fulfillment rates, though the SRx Network aims to simplify access to complex therapies.
• Creditors are affected by SRx Canada's CCAA proceedings, indicating potential restructuring or sale of assets, and the company's non-compliance with CWB loan covenants, making debt callable.
• Suppliers face risks related to the company's reliance on third-party suppliers for products, including potential supply shortages, price fluctuations, and disruptions.

Next Steps

• SRx Canada to complete a Sale Process or implement a restructuring plan under CCAA proceedings.
• Company to submit a plan to NYSE American by November 13, 2025, to regain compliance with listing standards by July 14, 2026.
• Company intends to seek to increase its authorized capital and amend the Registration Statement to register an additional $972.45 million of Common Stock under the ELOC Purchase Agreement.
• Management to continue implementing cost control measures and operational efficiencies.
• Management to scale higher-margin service lines and expand commercial footprint.
• Management to evaluate monetization or divestiture of non-core assets.
• Management to continue discussions with existing and potential lenders to restructure or refinance outstanding debt and obtain covenant waivers.
• Halo to continue driving brand awareness and innovation, shifting media investment to Amazon and Chewy platforms.
• Company to file a registration statement with the SEC covering the resale of Common Shares issuable upon conversion of July Notes or exercise of July Warrants.
• Company to file a registration statement with the SEC to register for resale the Common Stock issuable upon conversion of Series A Preferred Stock and exercise of October Warrants.

Key Dates

Recommendation

The company is in a highly precarious financial position, marked by substantial net losses, a significant accumulated deficit, and a going concern warning from its independent auditors. Its primary Canadian subsidiary is undergoing creditor protection (CCAA proceedings), and the company is non-compliant with key loan covenants and NYSE American listing standards, indicating severe operational and financial instability. While recent capital raises provide some liquidity, the impending significant dilution from the Keystone ELOC (40.64% of fully diluted shares) and the continued operating losses in the pet food segment suggest further downside risk for shareholders. The strategic shifts and industry tailwinds are overshadowed by immediate and severe financial distress, making the stock a strong sell for seasoned investors.

Keywords

Specialty Pharmacy, Pet Health, SEC Filing, S-1 Registration, SRx Health Solutions, Halo Purely for Pets, Keystone Capital, Equity Line of Credit, Convertible Notes, Warrants, CCAA Proceedings, Going Concern, Dilution, NYSE American, Financial Reporting, Healthcare Services Canada, Pet Food, Acquisitions, Corporate Restructuring, Risk Factors